Anti-VEGF antibody compositions and methods
US9421256B2 · kind B2 · utility
5Cited by
13References
45Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 15, 2013 |
| Grant date | Aug 23, 2016 |
| Priority date | — |
| Expiry date | May 23, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols for treating cancer and other angiogenic diseases. Advantageous immunoconjugate compositions and methods using the new VEGF-specific human antibodies are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.